1.	Phase III Study of Epratuzumab in Patients With Rituximab-Refractory Low-Grade Follicular B-Cell Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0009041, IM-T-hLL2-07, UCLA-BB-IND-7124, NCI-G01-2004, NCT00022685
2.	Phase I/II Study of Immunotherapy with Humanized Monoclonal Antibody LL2 in Patients with Recurrent Non-Hodgkin's Lymphoma (Summary Last Modified 03/1999) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: UNMC-289-97, IM-h-LL2-01, NCI-V97-1353
3.	Phase II Randomized Study of Epratuzumab in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0201056, AMGEN-AMG-412-159, NCI-G02-2094, NCT00042913
4.	Phase II Study of Epratuzumab and Rituximab in Patients With Refractory or Recurrent Low-Grade CD20-Positive B-Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0109058, AMGEN-20010138, NCT00054379
5.	Phase II Pilot Study of Epratuzumab Alone and in Combination With Re-Induction Combination Chemotherapy in Pediatric Patients With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (Part A closed to accrual as of 10/30/06) Phase: Phase II Type: Treatment Status: Closed Age: 2 to 31 Sponsor: NCI Protocol IDs: COG-ADVL04P2, ADVL04P2, NCT00098839
6.	Phase II Study of Epratuzumab and Rituximab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (CHOP) in Patients With Previously Untreated Stage II, III, or IV Diffuse Large B-Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0489, N0489, NCT00301821
7.	Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000572604, U10CA031946, CALGB-50701, NCT00553501
8.	Phase II Study of Epratuzumab, Cytarabine, and Clofarabine in Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Precursor B-Cell Acute Lymphoblastic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 16 and over Sponsor: NCI Protocol IDs: SWOG-S0910, S0910, NCT00945815
9.	Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: Other Protocol IDs: 2007-0160, NCT00941928
10.	Phase I Pilot Study of 131I-Labeled MOAB LL2 for B-Cell non-Hodgkin's Lymphoma (Summary Last Modified 06/95) Phase: Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: Protocol IDs: UCHSC-91264, NCI-V91-0216
11.	Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: LYMNHL0031, 200114861, 77550, CA09287, CA111827, NCT00398372